All In Biotech

Free tool

FAERS Monitor: Alyftrek

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218730 or its brand name (Alyftrek, Deutivacaftor, Tezacaftor, Vanzacaftor Calcium). Reports on generic versions are filed under their own applications.

Reports

789

Serious

375

48% of reports

Hospitalization

222

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hospitalisation68
  • headache53
  • anxiety48
  • rash47
  • fatigue45
  • dyspnoea39
  • infective pulmonary exacerbation of cystic fibrosis34
  • diarrhoea33
  • liver function test increased33
  • nausea33
  • haemoptysis24
  • alanine aminotransferase increased23
  • gastrointestinal disorder23
  • mental disorder23
  • abdominal pain upper22

Reports by year received

View as table
YearReports
20242
2025344
2026443

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,370 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal34167.6120.55,432
liver function test increasedSignal3341.029.41,249
haemoptysisSignal2423.015.5483
mental disorderSignal2314.19.4267
hospitalisationSignal6811.89.4666
alanine aminotransferase increasedSignal2310.06.7178
gastrointestinal disorderSignal236.84.6109
anxietySignal484.53.4129
rashSignal472.92.257
abdominal pain upperSignal222.81.925
headacheSignal532.31.737
dyspnoea391.81.414
fatigue451.51.28
diarrhoea331.41.03
nausea331.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.